Pipeline

September 2, 2019
Company Drug/Device Medical Condition Status
CStone Pharmaceuticals avapritinib GIST Phase 1 trial initiated
CStone Pharmaceuticals CS3002 advanced solid tumors Phase 1 trial initiated enrolling subjects in Australia
Alkahest GRF6021 Primary hip or knee arthroplasty Phase 2 trial initiated enrolling 45 subjects
Mag Force AG NanoTherm therapy Cancer lesions for prostate cancer Phase 2 trial initiated enrolling 120 male subjects at the Texas Urology Group, the University of Texas, San Antonio and the University of Washington, Seattle
Aimmune Therapeutics, Inc. AR201 egg allergy Phase 2 trial initiated enrolling 84 children, adolescents and young adults ages 4 to 26 years of age with hen egg allergy at 15 sites in the U.S.
Fulcrum Therapeutics Losmapimod (selective p38alpha/beta MAPK inhibitor) facioscapulohumeral muscular dystrophy (FSHD) Phase 2b trial initiated enrolling subjects with genetically confirmed FSHD
Mitsubishi Tanabe Pharma Corporation ND0612 Parkinson's disease with motor fluctuations Phase 3 trial initiated enrolling 300 subjects with PD experiencing motor fluctuations, whose symptoms are no longer controlled by conventional treatments at approximately 120 sites globally
VenatoRx Pharmaceuticals cefepime/VNRX-5133 complicated urinary tract infection (cUTI) Phase 3 trial initiated enrolling 582 adult subjects with cUTI, including acute pyelonephritis
DiscGenics, Inc. IDCT degenerative disc disease (DDD) Fast Track designation granted by the FDA
CrystalGenomics, Inc. CG-745 pancreatic cancer Orphan Drug Designation granted by the FDA
Kyowa Kirin Co., Ltd. NOURIANZ (istradefylline) Parkinson’s disease Approval granted by the FDA
Eli Lilly and Company Taltz (ixekizumab) injection 80 mg/mL active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA) Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

New!

2019 Site Survey Reports

Learn More Here